Article
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Journal of hematology & oncology - 18 Aug 2022
Jiang Qian, Li Zongru, Qin Yazhen, Li Weiming, Xu Na, Liu Bingcheng, Zhang Yanli, Meng Li, Zhu Huanling, Du Xin, Chen Suning, Liang Yang, Hu Yu, Liu Xiaoli, Song Yongping, Men Lichuang, Chen Zi, Niu Qian, Wang Hengbang, Lu Ming, Yang Dajun, Zhai Yifan, Huang Xiaojun
Abstract excerpt
BACKGROUND: BCR-ABL1T315I mutations confer resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Olverembatinib is a new potent BCR-ABL1 TKI with preclinical activity against T315I-mutated CML. In phase 1/2 studies, we explored the safety and efficacy of olverembatinib in Chinese adults with TKI-resistant CML in the chronic phase (CML-CP) and accelerated phase (CML-AP). METHODS: In...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.